Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Assets (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Assets for 14 consecutive years, with $255.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets rose 9.75% year-over-year to $255.9 million, compared with a TTM value of $255.9 million through Dec 2025, up 9.75%, and an annual FY2025 reading of $255.9 million, up 9.75% over the prior year.
  • Assets was $255.9 million for Q4 2025 at Heron Therapeutics, up from $249.0 million in the prior quarter.
  • Across five years, Assets topped out at $404.2 million in Q2 2021 and bottomed at $201.2 million in Q2 2023.
  • Average Assets over 5 years is $257.5 million, with a median of $239.9 million recorded in 2022.
  • The sharpest move saw Assets crashed 39.65% in 2022, then increased 12.76% in 2025.
  • Year by year, Assets stood at $305.7 million in 2021, then dropped by 17.91% to $251.0 million in 2022, then decreased by 11.33% to $222.5 million in 2023, then grew by 4.78% to $233.1 million in 2024, then grew by 9.75% to $255.9 million in 2025.
  • Business Quant data shows Assets for HRTX at $255.9 million in Q4 2025, $249.0 million in Q3 2025, and $232.1 million in Q2 2025.